Lanreotide Autogel® in acromegaly and neuroendocrine tumors

Therapy

Volumn 4, Issue 1, 2007, Pages 9-29

  Caron, Philippe ^a  

^a Sercvice d'Endocrinologie et Maladies Métaboliques ^*  (France)

Author keywords

Acromegaly; Carcinoid syndrome; Dopamine agonists; Growth hormone antagonist; Lanreotide; Lanreotide Autogel ; Octreotide pegvisomant; Somatostatin analog

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; LANTREOTIDE AUTOGEL; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; PROLACTIN; SOMATOMEDIN C; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; UNCLASSIFIED DRUG; VAPREOTIDE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACROMEGALY; ADD ON THERAPY; AQUEOUS SOLUTION; AREA UNDER THE CURVE; BILE DUCT DISEASE; CARCINOGENICITY; CARCINOID SYNDROME; CLINICAL TRIAL; CONTINUOUS INFUSION; COPING BEHAVIOR; CYTOREDUCTIVE SURGERY; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GALLSTONE; GAMMA KNIFE RADIOSURGERY; GASTROINTESTINAL DISEASE; GLUCOSE TOLERANCE; GROWTH HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPOPHYSECTOMY; HYPOPHYSIS ADENOMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LINEAR ACCELERATOR; MEDICAL DECISION MAKING; NAUSEA; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PATIENT CARE; POSTMARKETING SURVEILLANCE; PROTON THERAPY; RECEPTOR BINDING; REPRODUCTIVE TOXICITY; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN REDNESS; SUSTAINED RELEASE FORMULATION; SYMPTOM; SYRINGE; TERATOGENICITY; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 33847294657     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.4.1.9     Document Type: Review

References (85)

1. Giustina A, Barkan A, Casanueva FF et al.: Criteria for cure of acromegaly: a consensus statement. J. Clin. Endocrinol. Metab. 85, 526-529 (2000).
2. Melmed S, Casanueva FF, Cavagnini F et al.: Consensus statement: medical management of acromegaly. Eur. J Endocrinol. 153, 737-740 (2005).
3. Paisley A, Trainer PJ: Recent developments in the therapy of acromegaly. Expert Opin. Investig Drugs 15(3), 251-256 (2006).
4. Orme SM, McNally RJQ, Cartwright RA, Belchetz PE: Mortality and cancer incidence in acromegaly: a retrospective cohort study. J. Clin. Endocrinol. Metab. 83, 2730-2734 (1998).
5. Society for Endocrinology. The use of somatostatin analogues and the GH receptor antagonist in patients with acromegaly. September (2006) www.endocrinology.org/policy
6. Swearingen B, Barker FG, Katznelson L et al.: Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab. 83, 3419-3426 (1998).
7. Fahlbusch R, Honegger J, Buchfelder M: Surgical management of acromegaly. Endocrinol. Metab. Clin. North Am. 21, 669-692 (1992).
8. Powell JS, Wardlaw SL, Post KD et al.: Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor 1 to define cure. J. Clin. Endocrinol. Metab. 85, 2068-2071 (2000).
9. Page MD, Dieguez C, Valcavi R et al: Growth hormone (GH) responses to arginine and L-dopa alone and after GHRH pre-treatment. Clin. Enodocrinol. (Oxf.) 28, 551-558 (1988).
10. Oppizzi G, Liuzzi A, Chiodin P et al: Dopaminergic treatment of acromegaly: different effects on hormone secretion and tumor size. J. Clin. Endocrinol. Metab. 58, 988-992 (1984).
11. Davies PH, Stewart SE, Lancrarjan J et al.: Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin. Endocrinol. (Oxf.) 48, 311-316 (1998).
12. Chanson P, Leselbaum A, Blumberg J et al: Efficacy and tolerability of the long-acting somatostatin analogue lanreotide in acromegaly: a 12-month multicentre study of 58 acromegalic patients. French Multicentre Study Group on Lanreotide in Acromegaly. Pituitary 2, 269-276 (2000).
13. Trainer PJ, Drake WM, Katznelson L et al: Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 342, 1171-1177 (2000).
14. AACE guidelines: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocrine Practice 10(3), 214-225 (2004).
15. Melmed S, Casanueva FF, Cavagnini F et al.: Consensus. Guidelines for acromegaly management. J. Clin. Endocrinol. Metab. 87(9), 4054-4058 (2002).
16. Hofland LJ, Lamberts SW: The pathophysiological consequences of somatostatin receptor internalisation and resistance. Endocr. Rev. 24, 28-47 (2003).
17. Muller AF, Van der Lely AJ: Pharmacological therapy for acromegaly: a critical review. Drugs 6, 1817-38 (2004).
18. Freda PU, Katznelson L, van der Lely AJ et al.: Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 90 (8). 4465-4473 (2005).
19. Bevan JS, Atkin SL, Atkinson AB et al.: Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J. Clin. Endocrinol. Metab. 87(10), 4554-4563 (2002).
20. Colao A, Ferone D, Marzullo P et al.: Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J. Clin. Endocrinol. Metab. 86(6), 2779-2786 (2001).
21. Pereira AM, Biermasz NR, Roelfsema F, Romijn JA: Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance. Treat. Endocrinol. 4, 43-53 (2005).
22. Bevan JS: The antitumoral effects of somatostatin analog therapy in acromegaly. J. Clin. Endocrinol. Metab. 90(3), 1856-1863 (2005).
23. Melmed S, Sternberg R. Cook D et al.: A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J. Clin. Endocrinol. Metab. 90(7), 4405-4410 (2005).
24. Morange I, De Boisvilliers F, Chanson P et al.: Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J. Clin. Endocrinol. Metab. 79, 145-151 (1994).
25. Caron P, Cogne M, Gusthiot-Joudet B et al.: Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur. J. Endocrinol. 132, 320-325 (1995).
26. Caron P, Morange-Ramos I, Cogne M et al: Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J. Clin. Endocrinol. Metab. 82, 18-22 (1997).
27. Baldelli R, Colao A, Razzore P et al.: Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J. Clin. Endocrinol. Metab. 85, 4099-4103 (2000).
28. Ruszniewski P, Ish-Shalom S, Wymenga M et al.: Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology. 80, 244-251 (2004).
29. Bajetta E, Procopio G, Catena L et al: Lanreotide Autogel® every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well-differentiated neuroendocrine tumours: a Phase III study. Cancer 107 (10), 2474-2481 (2006).
30. Ducreux M, Ruszniewski P, Chayvialle JA et al: The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am. J. Gastroenterol. 95(11), 3276-3281 (2000).
31. Wymenga ANM, Eriksson B, Salmela P et al.: Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol l7(4), 1111-1117 (1999).
32. Abs R Verhelst J, Maiter D et al.: Cabergoline in the treament of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab. 83(2), 374-378 (1998).
33. Van der Lely AJ, Hutson RK, Trainer PJ et al.: Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 358(9295), 1754-1759 (2001).
34. Somavert® (Pegvisomant) 10mg, 15mg, 20mg Summary of Product Characteristics. Pfizer Inc. NY, USA, 13 November (2002).
35. Colao A, Pivonello R, Auriemma RS et al.: Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur. J. Endocrinol. 154, 467-477 (2006).
36. Sheppard MC. Primary medical therapy for acromegaly. Clin. Endocrinol. 58, 1387-399 (2003).
37. Valéry C, Artzner F, Robert B et al.: Self-association process of a peptide in solution: from β-sheet filaments to large embedded nanotubes. Biophys. J. 86, 2484-2501 (2004).
38. Patel YC, Srikant CB: Subtype selectivity of peptide analogues for all five cloned human somatostatin receptors (hSSTR 1-5). Endocrinology. 135, 2814-2817 (1994).
39. Patel YC: Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest. 20, 348-367 (1997).
40. de Herder WW, Lamberts SW: Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr. Opin. Oncol. 14, 53-57 (2002).
41. Hofland LJ, Lamberts SW: Somatostatin receptors in pituitary function, diagnosis and therapy. Front. Horm. Res. 32, 235-252 (2004).
42. Bruns C, Lewis I, Briner U et al.: SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 146, 707-716 (2002).
43. Antonijoan RM, Barbanoj MJ, Peraire C et al.: Pharmacokinetics of a new Autogel® formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J. Pharm. Phamacol. 56, 471-476 (2004).
44. Boscani PF, Caglioni P, Crivelli F et al.: The bioavailability and dose-proportionality of lanreotide Autogel®, 60, 90 and 120mg, after deep subcutaneous injection: an open-label, parallel-group, randomized study in healthy volunteers. Presented at: 12th International Congress of Endocrinology. Lisbon, Portugal, 31 August-4 September 2004.
45. Kuhn JM, Legrand A, Ruiz JM et al.: Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br. J. Clin. Pharmacol. 38, 213-219 (1994).
46. Astruc B, Marbach P, Bouterfa H et al: Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J. Clin. Pharmacol. 45, 836-844 (2005).
47. Bronstein M, Musolino N, Jallad R et al.: Pharmacokinetic profile of lanreotide Autogel® in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120mg every 28 days. Clin. Endocrinol. 63, 514-519 (2005).
48. Cendros JM, Peraire C, Troconiz IF, Obach R: Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel®. Metabolism 54, 1276-1281 (2005).
49. Tomlinson B, Thomas GN, Lan IW et al.: The pharmacokinetic profile of the somatostatin analogue lanreotide in patients with chronic hepatic insufficiency. Clin. Pharmacokinet. 45(10), 1003-1011 (2006).
50. Somatuline Autogel® 60mg, 90mg, 120mg Summary of Product Characteristics. Ipsen Ltd, Slough, UK (2001).
51. Caron Ph, Beckers A, Cullen DR et al.: Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel®) in the management of acromegaly. J. Clin. Endocrinol. Metab. 87, 99-104 (2002).
52. Caron Ph, Bex M, Cullen DR et al.: One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel®. Clin. Endocrinol. 60, 734-740 (2004).
53. Ramis J, Cendros J-M, Catus F, Schopohl JS: Pharmacokinetics and pharmacodynamics of lanreotide Autogel® after multiple subcutaneous administration in patients with acromegaly: a 52-week, multi-centre, randomized study. Presented at: 12th International Congress of Endocrinology. Lisbon, Portugal, 31 August-4 September 2004.
54. The Global Study Group for Lanreotide Autogel® in Acromegaly. Rapid and sustained reduction of serum growth hormone (GH) and insulin-like growth factor (IGF)-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a 52-week, multicentre, randomized study. Presented at: 12th International Congress of Endocrinology. Lisbon, Portugal, 31 August-4 September 2004.
55. Chanson P: on behalf of Lanreotide Autogel® 081 study investigators. Efficacy and safety of lanreotide Autogel® in the treatment of Acromegaly: a Phase III multicentre open trial. Presented at: 86th Annual Meeting of the Endocrine Society. New Orleans, USA, 16-19 June 2004 (Poster P1-373).
56. Gutt B, Bidlingmaier M, Kretschmar K et al.: Four-year follow-up of acromegalic patients treated with new long-acting formulation of lanreotide (lanreotide Autogel®). Exp. Clin. Endocrinol. Diabetes 113, 139-144 (2005).
57. Caron Ph, Cogne M, Raingeard I et al.: Effectiveness and tolerability of 3-year lanreotide Autogel® treatment in patients with acromegaly. Clin. Endocrinol. 64, 209-214 (2006).
58. Marek J, Paget M-A, Catus F, Colao A: Comparable long-term efficacy of lanreotide and octreotide: results of a 12-month observational study in acromegaly. Presented at: 88th Annual Meeting of the Endocrine Society. Boston, USA, 24-27 June 2006 (Poster P1-681).
59. Van Thiel SW, Romijn JA, Biermasz NR et al.: Octreotide long-acting repeatable and lanreotide Autogel® are equally effective in controlling growth hormone secretion in acromegalic patients. Eur. J. Endocrinol. 150, 489-495 (2004).
60. Ashwell SG, Bevan JS, Edwards OM et al.: The efficacy and safety of lanreotide Autogel® in patients with acromegaly previously treated with octreotide LAR. Eur. J. Endocrinol. 150, 473-480 (2004).
61. Alexopoulou O, Abrams P, Verhelst J et al.: Efficacy and tolerability of lanreotide Autogel® therapy in acromegalic patients previously treated with octreotide LAR. Eur. J. Endocrinol. 151, 317-324 (2004).
62. Godwin JD: Carcinoid tumors. An analysis of 2837 cases. Cancer. 2, 560-569 (1975).
63. Oberg K: Neuroendocrine tumours. Ann Oncol. 7, 453-463 (1996).
64. Kvols LK: Therapy of the malignant carcinoid syndrome. Endocrinol. Metab. Clin. North Am. 2, 557-568 (1989).
65. O'Toole D, Ducreux M, Bommelaer G et al.: Treatment of carcinoid syndrome, a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability and tolerance. Cancer 88, 770-776 (2000).
66. Oberg K, Kvols L, Caplin M et al.: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann. Oncol. 15, 966-973 (2004).
67. Ruszniewski P, Ducreux M, Chayvialle JA et al.: Treatment of carcinoid syndrome with the long-acting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 39, 279-283 (1996).
68. Ricci S, Antanuzzo A, Galli L et al.: Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am. J. Clin. Oncol. 23, 412-415 (2000).
69. Öberg K., Astrup L, Eriksson B et al., Members of Nordic NE Tumour Group: Guidelines for the management of gatroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Acta Oncologica, 43(7), 617-625 (2004).
70. Ruszniewski P, Ish-Shalom S, Wymenga M et al.: Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 80, 244-251 (2004).
71. Rubin J, Ajani W, Schirmmew W et al.: octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 17(2), 600-606 (1999).
72. Taal BG, Smits ME: A case study of carcinoid crisis successfully treated with lanreotide Autogel®. Presented at: 3rd Annual ENETS Conference. Prague, Czech Republic, 22-24 March 2006 (Abstract).
73. Sandostatin (Octreotide) LAR 10mg, 20mg, 30mg Summary of Product Characteristics, 3 June 2004.
74. Ciccarelli A, Daly A, Beckers A: Lanreotide Autogel® for acromegaly. Treat. Endocrinol. 3, 77-81 (2004).
75. Gilroy JJ, James RA: Optimizing somatostatin analog therapy in acromegaly. Long-acting formulations. Treat. Endocrinol. 1, 149-154 (2002).
76. Vitale G, Pivonello, Ferone D et al.: The role of somatostatin receptors in the medical treatment of acromegaly. Dig. Liver Dis. 36(Suppl. 1), S55-S59 (2004).
77. Bevan JS, Newell-Price J, Wass JAH and the Lanreotide Autogel® Self-Injection Study Group: An open label, controlled study to assess the ability of patients with acromegaly, or their partners, to administer Somatuline Autogel®. Presented at: The Joint Meeting of the European Congress of Endocrinology and British Endocrine Society. Glasgow, UK, 1-5 April 2006.
78. Lucas T, Astorga R and the Spanish-Portuguese Multicentre Autogel® Study Group for Acromegaly: Efficacy of lanreotide Autogel® administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles, 30 mg: a Phase III trial. Clin. Endocrinol. 65(3), 320-326 (2006).
79. Beck-Peccoz P, degli Uberti E.C, Mariotti S et al.: Efficacy of lanreotide Autogel®, 120mg, in patients with acromegaly previously treated with octreotide: Phase III, open, multicentre, longitudinal study. Presented at: European Congress of Endocrinology. Goteborg, Sweden, 3-7 September 2005.
80. Feenstra J, de Herder WW, ten Have SM et al.: Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365, 1644-1646 (2005).
81. Culler MD: Evolving concepts in the quest for advanced therapeutic analogues of somatostatin. Dig. Liv Dis. 36, S17-S25 (2004).
82. Jaffe CA, Barkan AL: Treatment of acromegaly with dopamine agonists. Endocrinol. Metab. Clin. North Am. 21, 713-735 (1992).
83. Flogstad AK, Halse J, Bakke S et al.: Sandostatin LAR in acromegalic patients: long-term treatment. J. Clin. Endocrinol. Metab. 82, 23-28 (1997).
84. Jaquet P, Gunz G, Saveanu A et al.: BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J. Endocrinol. Invest. 28(Suppl. 1), 21-27 (2005).
85. Van Der Lely AJ, de Herder WW, Feelders RA et al.: A single-dose comparison of the acute effects between the new somatostatin analogue SOM230 and octreotide in acromegalic patients. J. Clin. Endocrinol. Metab. 89(2), 638-645 (2004).